Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Ischl – page 20

307 clinical trials in Bad Ischl, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Ischl at a glance
307
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

307 trials in Bad Ischl

Open in trial search

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen - Cilag International

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Sleep disorder+1

Not recruiting

Study on Elinzanetant for Treating Sleep Disturbances in Menopausal Women

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Astrazeneca AB

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Astrazeneca AB

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Breast cancer

Not recruiting

Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Ischl

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focused on Chronic Obstructive Pulmonary Disease (COPD) treatment optimization through combination therapy approaches. Studies explore the effectiveness of triple therapy combinations including bronchodilators and anti-inflammatory medications.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Treatment Optimization

Clinical investigations aim to improve patient outcomes in moderate to severe COPD cases.

02 Pulmonary Therapeutics

Advanced research examining the efficacy of benralizumab in treating patients with moderate to very severe COPD. Focus on reducing exacerbation frequency in patients with elevated blood eosinophils.

  • Exacerbation Management
  • Targeted Therapy
  • Disease Control

Studies specifically target patients with a history of frequent COPD exacerbations.

03 Respiratory Care Innovation

Development of new therapeutic approaches using metered-dose inhalers for COPD management. Research combines multiple active ingredients to achieve optimal bronchodilation and anti-inflammatory effects.

  • Medication Delivery Systems
  • Combination Therapies
  • Treatment Efficacy

Emphasis on improving delivery methods and treatment effectiveness for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.